Related references
Note: Only part of the references are listed.Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria
Sanne Franzen et al.
ALZHEIMERS & DEMENTIA (2022)
What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?
Joshua D. Grill et al.
JAMA NEUROLOGY (2022)
Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment
Timothy S. Anderson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
Rema Raman et al.
JAMA NETWORK OPEN (2021)
2021 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2021)
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Olivier J. Wouters et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance
Stephen E. Kimmel et al.
ANNALS OF INTERNAL MEDICINE (2020)
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia A Randomized Clinical Trial
Suzanne Craft et al.
JAMA NEUROLOGY (2020)
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease A Randomized Clinical Trial
Christopher H. van Dyck et al.
JAMA NEUROLOGY (2019)
Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease
Christopher R. Beam et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease A Randomized Clinical Trial
Michael S. Rafii et al.
JAMA NEUROLOGY (2018)
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Jeffrey Cummings
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
A phase 3 trial of IV immunoglobulin for Alzheimer disease
Norman R. Relkin et al.
NEUROLOGY (2017)
Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006-2015
Ileana Baldi et al.
BMJ OPEN (2017)
Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials
Caroline S. Bennette et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials
Caroline S. Bennette et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions
Keith N. Fargo et al.
ALZHEIMERS & DEMENTIA (2016)
Innovation in the pharmaceutical industry: New estimates of R&D costs
Joseph A. DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2016)
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
R. Scott Turner et al.
NEUROLOGY (2015)
Recruitment of participants to a multiple sclerosis trial: The CombiRx experience
Minal J. Bhanushali et al.
CLINICAL TRIALS (2014)
Prevalence, Characteristics, and Publication of Discontinued Randomized Trials
Benjamin Kasenda et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Evaluating the Impact of Patient Recruitment and Retention Practices
Mary Jo Lamberti et al.
DRUG INFORMATION JOURNAL (2012)
Recruitment methods for united states Alzheimer disease prevention trials
L. S. Schneider
JOURNAL OF NUTRITION HEALTH & AGING (2012)
The incidence of MCI differs by subtype and is higher in men The Mayo Clinic Study of Aging
R. O. Roberts et al.
NEUROLOGY (2012)
Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease
Pierre N. Tariot et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Competing for patients: an ethical framework for recruiting patients with brain tumors into clinical trials
George M. Ibrahim et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
M. Sano et al.
NEUROLOGY (2011)
A phase II trial of huperzine A in mild to moderate Alzheimer disease
M. S. Rafii et al.
NEUROLOGY (2011)
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease A Randomized Trial
Joseph F. Quinn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials
Joshua D. Grill et al.
ALZHEIMERS RESEARCH & THERAPY (2010)
High-dose B vitamin supplementation and cognitive decline in Alzheimer disease - A randomized controlled trial
Paul S. Aisen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
How redesigning AD clinical trials might increase study partners' willingness to participate
Jason Karlawish et al.
NEUROLOGY (2008)
Recruiting subjects for acute stroke trials - A meta-analysis
JS Elkins et al.
STROKE (2006)
Vitamin E and donepezil for the treatment of mild cognitive impairment
RC Petersen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial
PS Aisen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Effect of early patient enrollment on the time to completion and publication of randomized controlled trials
AB Haidich et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2001)
What makes clinical research ethical?
EJ Emanuel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
